Literature DB >> 11518869

Reduced susceptibility to azithromycin and high percentages of penicillin and tetracycline resistance in Neisseria gonorrhoeae isolates from Manaus, Brazil, 1998.

J A Dillon1, J P Rubabaza, A S Benzaken, J C Sardinha, H Li, M G Bandeira, E dos Santos Fernando Filho.   

Abstract

BACKGROUND: The identification of Neisseria gonorrhoeae isolates resistant to antimicrobial agents currently recommended for the treatment of gonococcal infections continues to escalate globally. Thus, in some areas, resistance to fluoroquinolone drugs is commonplace; several reports document resistance to third-generation cephalosporins, and the sporadic isolation of spectinomycin-resistant isolates continues unabated. Gonococcal resistance to azithromycin, an antibiotic used for the primary treatment of gonococcal infections in some Latin American countries, also has been described. Because the prevalence of resistant isolates is insufficiently documented in many areas of Latin America, the efficacy of locally recommended therapies for gonococcal infections is often unknown. GOAL: To determine the antimicrobial susceptibility and strain types of N gonorrhoeae isolates collected in Manaus, Brazil. These data will establish antimicrobial susceptibility baseline data for the region as a reference point for future surveillance. STUDY
DESIGN: Consecutive N gonorrhoeae isolates from urethral and endocervical specimens were collected and examined for identity, antimicrobial susceptibility, and strain type (plasmid content, tetM type, auxotype, and serovar).
RESULTS: Most of the isolates (65/81; 85.2%) were resistant to tetracycline, penicillin, or both, with the majority (n = 62) carrying plasmid-mediated resistance to tetracycline (tetracycline-resistant N gonorrhoeae [TRNG]). All of the TRNG contained the Dutch-type tetM plasmid, and 18 were A/S class NR/IA-02. Penicillinase-producing N gonorrhoeae comprised 8.2% (7/81) of the isolates. Of these seven isolates, four also were TRNG, and two carried chromosomal resistance to tetracycline. The isolates were susceptible to ciprofloxacin, spectinomycin, and ceftriaxone. However, 23 isolates were characterized by reduced susceptibility to azithromycin (MIC, 0.25-0.5 microg/ml), and one isolate had reduced susceptibility to ciprofloxacin (MIC, 0.25 microg/ml).
CONCLUSIONS: This study supports the continued use of third-generation cephalosporins, spectinomycin, and fluoroquinolone drugs for the primary treatment of gonococcal infections in Manaus. The occurrence of isolates with reduced susceptibility to azithromycin and ciprofloxacin underscores the importance of ongoing antimicrobial susceptibility monitoring to support decisions regarding appropriate drugs for the treatment of gonococcal infections.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11518869     DOI: 10.1097/00007435-200109000-00008

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  9 in total

1.  Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.

Authors:  Vanessa G Allen; David J Farrell; Anuradha Rebbapragada; Jingyuan Tan; Nathalie Tijet; Stephen J Perusini; Lynn Towns; Stephen Lo; Donald E Low; Roberto G Melano
Journal:  Antimicrob Agents Chemother       Date:  2010-11-22       Impact factor: 5.191

2.  Longitudinal analysis of the evolution and dissemination of Neisseria gonorrhoeae strains (Saskatchewan, Canada, 2005 to 2008) reveals three major circulating strains and convergent evolution of ciprofloxacin and azithromycin resistance.

Authors:  Sinisa Vidovic; Sidharath D Thakur; Greg B Horsman; Paul N Levett; Vahid Anvari; Jo-Anne R Dillon
Journal:  J Clin Microbiol       Date:  2012-09-12       Impact factor: 5.948

3.  Molecular characterization of quinolone-resistant Neisseria gonorrhoeae isolates from Brazil.

Authors:  Aline A Uehara; Efigênia L T Amorin; Maria de Fátima Ferreira; Claudia F Andrade; Maysa B M Clementino; Ivano de Filippis; Felipe P G Neves; Tatiana de C A Pinto; Lúcia M Teixeira; Marcia Giambiagi-Demarval; Sérgio E L Fracalanzza
Journal:  J Clin Microbiol       Date:  2011-10-05       Impact factor: 5.948

4.  Acquired macrolide resistance genes in pathogenic Neisseria spp. isolated between 1940 and 1987.

Authors:  Sydney Cousin; William L H Whittington; Marilyn C Roberts
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

5.  Developing a system to predict laboratory-confirmed chlamydial and/or gonococcal urethritis in adult male emergency department patients.

Authors:  Roland C Merchant; Dina M DePalo; Tao Liu; Josiah D Rich; Michael D Stein
Journal:  Postgrad Med       Date:  2010-01       Impact factor: 3.840

6.  Plasmid-mediated resistance to tetracyclines among Neisseria gonorrhoeae strains isolated in Poland between 2012 and 2013.

Authors:  Beata Młynarczyk-Bonikowska; Marlena Kujawa; Magdalena Malejczyk; Grażyna Młynarczyk; Sławomir Majewski
Journal:  Postepy Dermatol Alergol       Date:  2016-12-02       Impact factor: 1.837

Review 7.  Multiresistant Neisseria gonorrhoeae: a new threat in second decade of the XXI century.

Authors:  Beata Młynarczyk-Bonikowska; Anna Majewska; Magdalena Malejczyk; Grażyna Młynarczyk; Sławomir Majewski
Journal:  Med Microbiol Immunol       Date:  2019-12-04       Impact factor: 3.402

Review 8.  On the pathway to better birth outcomes? A systematic review of azithromycin and curable sexually transmitted infections.

Authors:  R Matthew Chico; Berkin B Hack; Melanie J Newport; Enesia Ngulube; Daniel Chandramohan
Journal:  Expert Rev Anti Infect Ther       Date:  2013-11-06       Impact factor: 5.091

9.  Antimicrobial Resistance in Neisseria gonorrhoeae: Proceedings of the STAR Sexually Transmitted Infection-Clinical Trial Group Programmatic Meeting.

Authors:  Anthony D Cristillo; Claire C Bristow; Elizabeth Torrone; Jo-Anne Dillon; Robert D Kirkcaldy; Huan Dong; Yonatan H Grad; Robert A Nicholas; Peter A Rice; Kenneth Lawrence; David Oldach; William Maurice Shafer; Pei Zhou; Teodora E Wi; Sheldon R Morris; Jeffrey D Klausner
Journal:  Sex Transm Dis       Date:  2019-03       Impact factor: 2.830

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.